Polatuzumab in Relapsed/Refractory DLBCL Case

Author: Dr. Yaqeen Abduallah, University of Manitoba
Reviewer: Dr. Roopesh Kansara

Learning Objectives

As the end of this self-assessment module, participants should be able to:
1. Describe the treatment options for patients with relapsed/refractory DLBCL
2. Described the mechanism of action of polatuzumab
3. Describe the most common adverse reactions of polatuzumab

Scientific Planning Committee

Dr. Pallavi Ganguli – Resident Physician, Hematology
Dr. Danyal Ladha – Resident Physician, Hematology
Dr. Joanne Britto – Clinical Fellow, Malignant Hematology (Lymphoproliferative Disorders)
Dr. Yan Xu – Fellow Physician, Hematology/Thrombosis
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician,
Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflict of Interest: None